Latest Asx News

Hotel Property Investments (HPI) reported a solid $16.7 million statutory profit for H1 FY25, alongside a 3.2% rise in distributions and a successful debt refinancing that extends maturity and reduces costs.

Hotel Property Investments has announced significant leadership changes following increased shareholding by Charter Hall and Hostplus, signaling a strategic pivot for the property investment firm.

Hotel Property Investments (HPI) reported a robust half-year profit of A$16.7 million, driven by rising rental income and property valuations, while managing significant takeover defence costs amid Charter Hall Retail REIT and Hostplus bids.

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.

Aruma Resources is set to launch a 2,000-metre aircore drilling campaign at its Salmon Gums Gold Project, aiming to unlock new high-potential gold prospects identified through recent geological reinterpretations.

Tempest Minerals has signed a Memorandum of Understanding with Green Steel and Iron to develop a $3 billion hot briquette iron processing hub near its Yalgoo Project, aiming to supply high-grade magnetite for green steelmaking.

Enova Mining has reported multiple high-grade titanium dioxide intercepts exceeding 15% TiO2 at its CODA North project, highlighting significant multi-commodity potential alongside rare earth elements.

Nick Scali Limited has announced a fully franked ordinary dividend of AUD 0.30 per share for the six months ending December 2024, signaling steady shareholder returns.

Lord Resources has uncovered significant gravity anomalies at its Ilgarari Copper Project, revealing promising new drill targets and commencing an earn-in agreement to secure an 80% interest in the sulphide rights.

Nick Scali Limited reported a stronger-than-expected half-year profit, driven by solid ANZ performance, while its UK operations continue to face restructuring challenges amid store refurbishments.

Neuren Pharmaceuticals has secured a pivotal FDA Type C Meeting to discuss primary efficacy endpoints for its Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, advancing its rare disease drug development.

Miramar Resources has confirmed the Bangemall region as a significant new nickel-copper province following detailed Micro-XRF analysis of drill samples from its Mount Vernon Project, revealing disseminated nickel and copper sulphides. This breakthrough positions Miramar as a first-mover with a dominant landholding in a highly prospective area.